clinical trial · NCT01050218
Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
Wyeth is now a wholly owned subsidiary of Pfizer·phase3·terminated·n = 237
Diabetic Neuropathy, PainfulDesvenlafaxine Succinate Sustained-Release (DVS SR)
brief summary
The purpose of the study is to learn if long-term treatment with DVS SR is safe for treating the pain and other symptoms associated with diabetic peripheral neuropathy.
started
Jul 1, 2006
primary completion
Jan 1, 2009
completion
Jan 1, 2009
last updated
Dec 11, 2023
official title
A 9-Month Open-Label Extension Study of the Long-Term Safety of DVS SR in Outpatients With Pain Associated With Diabetic Peripheral Neuropathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol